Biological use influences the impact of inflammation on risk of major adverse cardiovascular events in rheumatoid arthritis

By sjmartinez • July 24, 2024

Karpouzas GA, Ormseth SR, van Riel PLCM, Gonzalez-Gay MA, Corrales A, Rantapää-Dahlqvist S, Sfikakis PP, Dessein P, Tsang L, Hitchon C, El-Gabalawy H, Pascual-Ramos V, Contreras-Yáñez I, Colunga-Pedraza IJ, Galarza-Delgado DA, Azpiri-Lopez JR, Semb AG, Misra DP, Hauge EM, Kitas G. Biological use influences the impact of inflammation on risk of major adverse cardiovascular events in rheumatoid arthritis. RMD Open. 2024 Jul 23;10(3):e004546. doi: 10.1136/rmdopen-2024-004546. PMID: 39043615.

Tags: Arthritis, biological therapy, cardiovascular diseases, Harbor UCLA, Inflammation, Publications, Rheumatoid, Rheumatology

Cefadroxil as Oral Transitional Therapy for Gram-Positive Bacteremia With or Without Non-Vertebral Osteomyelitis: A Multicenter Retrospective Cohort Study

Clark DC, Baden R, Banerjee J, Bedrossian R, Chute H, Davar K, Deng D, Donnelly M, Fernandez D, Goodman R, Gordon H, Harris E, Hutcheon[...]

Renal Outcomes of Triglyceride-Targeting Lipid-Lowering Therapies versus Statins in Patients with CKD

Naim MAAZ, Thomas F, Streja E, Davis RL, Kalantar-Zadeh K, Sumida K, Kovesdy CP. Renal Outcomes of Triglyceride-Targeting Lipid-Lowering Therapies versus Statins in Patients with[...]

A Review of Randomized Controlled Trials for Vitiligo Therapies Published Between 2013 and 2023

Maverakis Ramirez N, Jaeger ZJ, Lee DJ. A Review of Randomized Controlled Trials for Vitiligo Therapies Published Between 2013 and 2023. Cureus. 2026 Jul 8;18(7):e112280.[...]